Catalog No.
Product Name
Application
Product Information
Citations
-
Natural product
6-Prenylquercetin-3-Me ether is a natural product extracted from the leaves of Glycyrrhiza uralensis. It exhibits potent radical scavenging activity against DPPH, indicating its potential as an antioxidant. Additionally, this compound displays inhibitory activity against α-glucosidase, making it valuable for research in diabetes and metabolic disorders. -
α-Glucosidase Inhibitor
α-Glucosidase-IN-12 is a potent inhibitor of α-glucosidase, exhibiting an IC50 value of 10.20 μM. This compound effectively modulates carbohydrate digestion and absorption, making it valuable for research on metabolic disorders such as type 2 diabetes and obesity. Its use in biochemical assays provides insights into enzymatic activity and potential therapeutic strategies. -
α-glucosidase/Acetylcholinesterase Inhibitor
7β-Hydroxybufalin is a bufadienolide that acts as a potent inhibitor of α-glucosidase and acetylcholinesterase. Isolated from the venom of Bufo bufo gargarizans, this compound demonstrates significant biological activity relevant to the modulation of carbohydrate and neurotransmitter metabolism. 7β-Hydroxybufalin is utilized in research applications focused on metabolic disorders and neurodegenerative diseases. -
α-glucosidase inhibitor
α-Homonojirimycin is a potent inhibitor of α-glucosidase, an enzyme involved in carbohydrate metabolism. By blocking α-glucosidase activity, it effectively modulates glucose absorption, making it a valuable compound for research in diabetes and metabolic disorder studies. Its inhibitory properties are also applicable in exploring the roles of glycosidases in various biological processes. -
α-Glucosidase Inhibitor
4-Ethoxy-5,8-dihydroxy-3,4-dihydronaphthalen-1(2H)-one is a naphthalene derivative that functions as a weak α-glucosidase inhibitor. This compound, which can be isolated from the leaves of Cyclocarya paliurus, is relevant in the study of diabetes management. Its inhibitory activity on α-glucosidase suggests potential applications in carbohydrate metabolism research and glycemic control studies. -
GAA Agonist
5-C-heptyl-DNJ is a potent GAA agonist, exhibiting a Ki of 0.0047 μM. This compound enhances GAA activity through chaperone effects, making it valuable for research focused on lysosomal storage disorders and related biological pathways. Its ability to modulate GAA provides insights into enzyme replacement therapies and potential treatments for diseases associated with GAA deficiency. -
α-Glucosidase Inhibitor
α-Glucosidase-IN-16 is a potent inhibitor of α-glucosidase, exhibiting an IC50 value of 3.28 μM. This compound effectively lowers blood glucose levels in Streptozotocin-induced diabetic rats, demonstrating significant antidiabetic properties. Its use in research facilitates the exploration of therapeutic strategies for managing diabetes and related metabolic disorders. -
α-glucosidase Inhibitor
α-Glucosidase-IN-54 is a potent inhibitor of α-glucosidase, exhibiting an IC50 value of 0.011 mM. This compound, derived from Syzygium jambos, is valuable for research focused on glucose metabolism and diabetes management. Its inhibitory action makes it a useful tool for studying the mechanisms of carbohydrate digestion and potential therapeutic interventions for hyperglycemia. -
Alpha-Mannosidase Modulator
OMJ-4 is a modulator of mutant alpha-mannosidase that enhances its catalytic function. This compound promotes structural changes in the enzyme, increasing both the compactness and flexibility of the active site, which facilitates substrate binding. By inducing greater substrate reactivity, OMJ-4 decreases the activation energy needed for the enzymatic reaction. This reagent is significant for research focused on alpha-mannosidosis and related metabolic disorders. -
α-Glucosidase Inhibitor
α-Glucosidase-IN-29 is a potent inhibitor of α-glucosidase, displaying an IC50 value of 1.21 μM and a Ki value of 1.80 μM. This compound is primarily utilized in research focused on diabetes and associated metabolic disorders, where modulation of carbohydrate absorption is critical. Its mechanistic action allows for potential exploration in understanding the therapeutic effects against glycemic control and related physiological impacts. -
Endoplasmic Reticulum α-Glucosidases I and II inhibitor
EB-0176 is a potent inhibitor of endoplasmic reticulum α-glucosidases I and II, exhibiting IC50 values of 0.6439 μM and 0.0011 μM, respectively. This N-substituted derivative of valiolamine demonstrates broad-spectrum antiviral activity, positioning it as a valuable tool for research into antiviral agents targeting both existing and emerging viruses. Its ability to inhibit key glycosylation processes makes it significant for studies in virology and therapeutic development. -
Alpha-Glucosidase Inhibitor
Vitexin-2''-O-glucoside is a selective inhibitor of alpha-glucosidase, primarily extracted from flavonoids in hawthorn leaves. It reversibly inhibits α-glucosidase activity at the brush border of the small intestine, demonstrating a potent inhibitory effect. This compound is widely utilized in research related to type 2 diabetes and may serve as a promising candidate for therapeutic development in glycemic control. -
α-Glucosidase Inhibitor
PBI-6DNJ is a potent α-glucosidase inhibitor that functions as a multivalent glycosidase inhibitor. It demonstrates significant inhibitory activity against mouse α-glucosidase, with an affinity constant (Ki) of 0.14 μM. The compound also exhibits notable hypoglycemic effects, making it a valuable tool for research related to type 2 diabetes. -
α-Glucosidase Inhibitor
16-Oxoserratenediol is a serratene-type triterpenoid that functions as an α-glucosidase inhibitor, demonstrating an inhibition rate of 43.93% at a concentration of 100 μM. This compound is derived from Lycopodium cernuum L. and is primarily utilized in research related to diabetes management and metabolic disorders. Its mechanism of action contributes to the regulation of carbohydrate metabolism, making it a valuable tool for studying glycemic control in various biological contexts. -
α-glucosidase Inhibitor
Deacylhericene is an α-glucosidase inhibitor that demonstrates a potent inhibitory effect with an IC50 of 12.5 μM. This compound functions by effectively reducing the activity of α-glucosidase, making it a valuable reagent for studying carbohydrate metabolism. Its application is particularly relevant in diabetes research and the exploration of glycemic control mechanisms. -
Glycosidase Inhibitor
(3R,4R)-4-(Hydroxymethyl)pyrrolidin-3-ol functions as a glycosidase inhibitor. This compound demonstrates significant biological activity by modulating the activity of glycosidases, which are crucial in carbohydrate metabolism. It serves as an important intermediate for the synthesis of various biologically active molecules, making it valuable in chemical research and drug development applications. -
α-Glucosidase Inhibitor
2,3-Indolobetulonic acid functions as an α-glucosidase inhibitor, exhibiting an IC50 of 1.8 µM. This triterpenoid compound is significant in research related to glucose metabolism and diabetes management. It is valuable for studies focusing on carbohydrate digestion and its modulation within metabolic pathways. -
Antioxidant Agent
Tachioside is a potent antioxidant agent that inhibits nitric oxide production in lipopolysaccharide-stimulated RAW 264.7 cells, exhibiting an IC50 value of 12.14 μM. This compound demonstrates notable anti-obesity effects and possesses α-glucosidase inhibitory activity, making it a valuable reagent for research in oxidative stress, metabolic disorders, and inflammation. -
α-Glycosidase Inhibitor
Terrestrimine is a potent α-Glycosidase inhibitor, demonstrating an IC50 of 225.83 μM. This compound is significant in the study of metabolic disorders, as it can modulate carbohydrate metabolism and glycemic control. It serves as a valuable tool for researchers investigating the role of glycosidase enzymes in various metabolic conditions. -
Glycosidase Inhibitor
(-)-Adenophorine is a potent glycosidase inhibitor that specifically targets α-L-fucosidase, exhibiting an IC50 of 72 μM. This compound plays a crucial role in biochemical research by facilitating studies on glycoprotein metabolism and cellular signaling pathways. Its ability to modulate glycosidase activity makes it a valuable tool for investigating disease mechanisms and developing therapeutic strategies. -
Glucocerebrosidase Inhibitor
Glucocerebrosidase-IN-2 is a potent inhibitor of glucocerebrosidase, a critical enzyme in lipid metabolism linked to Gaucher disease. This quinazoline derivative enhances glucocerebrosidase translocation to lysosomes in patient-derived cells, particularly those with the N370S mutation. It effectively inhibits the hydrolysis of substrates such as 4-methylumbelliferone β-D-glucopyranoside and fluorescent glycosylceramide in N370S mutant tissues, exhibiting an AC50 of 25.29 μM. Glucocerebrosidase-IN-2 is valuable for research focused on therapeutic approaches for Gaucher disease and related lysosomal storage disorders. -
Hydrolase
Oligo-α-1,6-Glucosidase from Bacillus cereus ATCC7064 is a hydrolase enzyme that specifically targets and hydrolyzes oligosaccharides containing α-1,6-glycosidic bonds. This enzyme catalyzes the exo hydrolysis of α-1,6-glucoside linkages from nonreducing ends of substrates such as panose, palatinose, α-limit dextrins, and isomaltooligosaccharides. Oligo-α-1,6-Glucosidase plays a crucial role in the degradation of starch and glycogen, complementing the activity of α-amylase in the complete hydrolysis of amylopectin. Its applications include studies of carbohydrate metabolism and enzymatic processes involved in starch breakdown. -
α-Glucosidase Inhibitor
(-)-6β-Hydroxy-5β,8β,9β,10α-cleroda-3,13-dien-16,15-olid-18-oic acid serves as a potent α-Glucosidase inhibitor, demonstrating an IC50 value of 577.7 µM. This compound is valuable in research focused on carbohydrate metabolism and the management of postprandial hyperglycemia. Its ability to modulate α-glucosidase activity makes it a useful tool in studies related to diabetes and metabolic disorders. -
α-Glucosidase Inhibitor
α-Glucosidase-IN-38 is a potent inhibitor of α-glucosidase, with an IC50 value of 12.44±0.38 μM. This compound is significant for its role in the management of Diabetes Mellitus (DM) by reducing carbohydrate absorption in the intestines. It is useful for research applications focused on metabolic disorders and the development of diabetes therapies. -
α-Glucosidase Inhibitor
α-Glucosidase-IN-24 is a potent inhibitor of α-glucosidase, exhibiting an IC50 value of 451 μM. This compound is derived from the plant Swertia kouitchensis and is primarily used in research to study carbohydrate metabolism and its implications in conditions such as diabetes and obesity. Its inhibitory action on α-glucosidase makes it a valuable tool for exploring therapeutic strategies targeting metabolic disorders. -
α-Glucosidase Inhibitor
α-Glucosidase-IN-113 is a specific inhibitor of α-glucosidase, exhibiting an IC50 of 17.52 μM. This compound demonstrates antiglycating properties and effectively inhibits the formation of advanced glycation end-products. Its applications include research into type 2 diabetes and related metabolic disorders. -
Natural Product
5,4'-Dihydroxy-3,4,3'-trimethoxybibenzyl is a natural product isolated from Dendrobium infundibulum. This compound is primarily investigated for its potential biological activities, although it has been shown to lack inhibitory effects against α-glucosidase and pancreatic lipase. It serves as a valuable tool in research focused on understanding the pharmacological properties of natural compounds and their metabolic implications. -
α-Glucosidase Inhibitor
N-Formyldehydroanonaine is a potent inhibitor of α-glucosidase, exhibiting an IC50 value of 104.6 μM against yeast α-glucosidase. This compound is useful for research into diabetes mellitus, providing insights into the management of postprandial blood sugar levels through inhibition of carbohydrate breakdown. -
α-glucosidase Inhibitor
Prunetin 5-O-β-D-glucopyranoside is an isoflavone that functions as a potent uncompetitive inhibitor of α-glucosidase, exhibiting an IC50 of 56.05 μg/mL. This compound is derived from extracts of Potentilla astracanica and plays a significant role in modulating carbohydrate metabolism. It is particularly relevant for research applications focused on type-2 diabetes and the management of postprandial hyperglycemia. -
Glycosidase Inhibitor
Glycosidase-IN-2 is a potent glycosidase inhibitor classified as an azasugar. This compound exhibits hypoglycemic activity, making it valuable in researching mechanisms related to glucose metabolism and diabetes management. Its ability to modulate glycosidase activity provides insights into carbohydrate processing and potential therapeutic applications for glycemic control. -
α-Glucosidase Inhibitor
α-Glucosidase-IN-25 is a competitive inhibitor of α-glucosidase, exhibiting an IC50 value of 1.19 μM. This compound serves as a valuable tool in anti-diabetic research by inhibiting carbohydrate absorption and regulating postprandial blood glucose levels. Its ability to modulate α-glucosidase activity makes it a promising candidate for the development of therapeutic strategies targeting diabetes management. -
Beta-glucocerebrosidase Inhibitor
Glycosidase-IN-3 is a pyrimidine compound that acts as a selective inhibitor of beta-glucocerebrosidase. It has demonstrated significant biological activity relevant to the study of lysosomal storage disorders, particularly Gaucher's disease, as well as neurodegenerative conditions such as Parkinson's disease. This compound is suitable for use in research focused on these diseases and their underlying mechanisms. -
α-Glucosidase Inhibitor
α-Glucosidase-IN-14 is a potent inhibitor of α-glucosidase, exhibiting an IC50 value of 5.22 μM. This compound is valuable for studying carbohydrate metabolism and related disorders, particularly in the context of diabetes management. Its ability to inhibit α-glucosidase makes it a useful tool in pharmacological research aimed at developing therapies that modulate glucose absorption and metabolism. -
Antiallergic Agent
(3R,5S)-5'-Methoxyoctahydrocurcumin is a diarylheptanoid derived from Curcuma comosa, primarily targeting antiallergic mechanisms. This compound demonstrates significant activity in inhibiting β-hexosaminidase release and mast cell degranulation, making it a valuable tool in immunological studies. Its applications include research on various allergic conditions, such as asthma, where understanding the modulation of immune responses is critical. -
α-glucosidase Inhibitor
N-(E)-Caffeoyldopamine is an α-glucosidase inhibitor derived from Clerodendranthus Spicatus, demonstrating an inhibitory activity of 53.73% against the enzyme. This compound has significant potential for applications in diabetes research, where it can be utilized to explore mechanisms of glucose metabolism and regulation. Its role in modulating α-glucosidase activity makes it a valuable tool for studying carbohydrate absorption and related metabolic disorders. -
α-Glucosidase Inhibitor
α-Glucosidase-IN-70 is a potent α-glucosidase inhibitor with an IC50 of 31.1 μM, derived from the traditional Chinese herbal medicine Swertia mussotii. This compound is valuable for investigating the modulation of carbohydrate metabolism, particularly in the context of diabetes research. Its inhibitory action on α-glucosidase makes it a suitable candidate for further studies exploring therapeutic strategies to manage postprandial hyperglycemia. -
α-Glucosidase Inhibitor
α-Glucosidase-IN-111 is a selective inhibitor of α-glucosidase, demonstrating an IC50 of 34.99 μg/mL. In addition to its inhibitory effects on α-glucosidase, it exhibits strong antioxidant properties, effectively scavenging DPPH and ABTS free radicals with IC50 values of 5.33 and 5.84 μg/mL, respectively. This compound is valuable for research focused on type 2 diabetes and related metabolic disorders, making it a useful tool for studying glycemic control and oxidative stress mechanisms. -
Alpha-glucosidase Inhibitor
Valibose is an alpha-glucosidase inhibitor that plays a crucial role in regulating carbohydrate metabolism. It has been shown to improve metabolic disorders related to glucose and lipid levels, as well as alleviate nephropathy in Streptozotocin-induced diabetic rat models. This compound is valuable for research focused on diabetes and associated metabolic conditions. -
α±-Glucosidase Inhibitor
Chrysin 6-C-arabinoside 8-C-glucoside is an α±-glucosidase inhibitor that demonstrates significant potential in the management of type 2 diabetes. By inhibiting α-glucosidase activity, this compound can effectively reduce carbohydrate digestion and absorption, potentially leading to improved glycemic control. Its biological activity makes it a valuable tool for research into metabolic disorders and the development of antidiabetic therapies. -
α-glucosidase Inhibitor
α-Glucosidase-IN-22 is a benzimidazole derivative that serves as a potent inhibitor of α-glucosidase, exhibiting an IC50 value of 0.64 μM. This compound demonstrates significant anti-diabetic properties, making it a promising candidate for research in type 2 diabetes mellitus (T2DM). Its ability to modulate carbohydrate digestion positions α-Glucosidase-IN-22 as a valuable tool in glucose metabolism studies and diabetes management investigations. -
GCase Modulator
JZ-4109 is a potent β-Glucocerebrosidase (GCase) modulator, exhibiting an IC50 of 8 nM against wild-type recombinant GCase. This compound binds to an allosteric site at the GCase dimer interface, promoting dimerization and stabilizing both wild-type and GCase N370S mutant variants. JZ-4109 enhances GCase protein abundance, making it a valuable tool for research into Parkinson's disease and related conditions. -
Glycosidase Inhibitor
L-Afegostat (5-epi-Isofagomine) is a glycosidase inhibitor that targets β-Glucosidase, exhibiting enzyme inhibition with a Ki of 30 μM. This iminosugar plays a significant role in carbohydrate synthesis and is valuable for studying glycosidase-related metabolic processes. It is particularly useful in research focused on enzyme regulation and glycosylation mechanisms. -
α-Glucosidase Inhibitor
α-Glucosidase-IN-43 is a potent α-glucosidase inhibitor with an IC50 value of 4.32 μM, demonstrating significant hypoglycemic activity. This compound exhibits low toxicity in normal mouse fibroblasts and shows efficacy in vivo, effectively rescuing streptozotocin-induced diabetic rats. α-Glucosidase-IN-43 is valuable for investigating postprandial hyperglycemia and related metabolic disorders in diabetes research. -
α-glucosidase Inhibitor
Quercetin 3'-methoxy-3-O-α-L-arabinofuranoside is an α-glucosidase inhibitor, derived from the leaves and twigs of Fagus hayatae. This compound demonstrates weak inhibitory activity against α-glucosidase, an enzyme involved in carbohydrate metabolism. It serves as a valuable tool for research in glycemic control and metabolic studies. -
Glycosidase Inhibitor
Nojirimycin is a nitrogen-containing sugar analog that functions as a glycosidase inhibitor. Its unique structure includes a ring nitrogen atom, which acts as an isostere of the oxygen atom in sugar rings, effectively inhibiting the activity of glycosidases. This compound is valuable in biochemical research for studying enzymatic functions and exploring metabolic pathways involving glycosidases. -
Anti-hyperglycemic Agent
Anti-hyperglycemic agent-1 is a potent α-Glucosidase inhibitor, exhibiting an IC50 of 0.53 μM. This compound is primarily utilized in diabetes research to investigate mechanisms of glucose metabolism and control postprandial hyperglycemia. Its selective inhibition of α-Glucosidase makes it a valuable tool for studying the biochemical pathways involved in carbohydrate absorption and insulin sensitivity. -
Glycosidase
Agarase is a glycosidase enzyme that catalyzes the hydrolysis of agar into oligosaccharides. This biochemical process is pivotal in the study of polysaccharide degradation and has applications in food science, molecular biology, and biotechnology. Agarase's ability to produce oligosaccharides from agar enhances research into carbohydrate metabolism and the development of agarose-based products. -
α-Glucosidase Inhibitor
Falandioside B is an α-glucosidase inhibitor with an IC50 of 107.52 μM, effectively modulating carbohydrate metabolism. It exhibits antioxidant activity by scavenging ABTS radical cations, making it relevant for studies on oxidative stress. This compound is primarily utilized in research focused on managing postprandial hyperglycemia and its associated metabolic implications. -
α-Glucosidase Inhibitor
α-Glucosidase-IN-9 is a potent inhibitor of α-glucosidase, exhibiting an IC50 of 55.6 μM. This compound is relevant for research applications focused on type II diabetes, enabling the investigation of carbohydrate digestion and glucose absorption. Through its inhibitory action, α-Glucosidase-IN-9 provides a valuable tool for studying the metabolic implications associated with dysregulated glucose homeostasis. -
Human Glucocerebrosidase
Imiglucerase is a recombinant human glucocerebrosidase that catalyzes the hydrolysis of glucosylceramide into glucose and ceramide. This enzyme is primarily utilized in the research of type 1 (non-neuronopathic) and type 3 (chronic neuronopathic) Gaucher's disease. Imiglucerase facilitates studies on enzyme replacement therapy and its effects on cellular metabolism in Gaucher's disease pathophysiology.
